YD Bio Ltd
YDES
13 hedge funds and large institutions have $640K invested in YD Bio Ltd in 2026 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 0 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 1
63% more funds holding
Funds holding: 8 → 13 (+5)
0.18% more ownership
Funds ownership: 0.23% → 0.4% (+0.18%)
48% less capital invested
Capital invested by funds: $1.23M → $640K (-$589K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GWAG
Garrett Wealth Advisory Group
Weatherford,
Texas
|
+$378K |
| 2 |
Jane Street
New York
|
+$95.8K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$47.6K |
| 4 |
CCMW
Cypress Capital Management (Wyoming)
Sheridan,
Wyoming
|
+$13.4K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$11.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$282 |
YDES Hedge Fund Activity: Q2 2026 in Review
13 of the 8,343 institutional investors tracked by Wall St. Rank reported a position in YD Bio Ltd (YDES) for Q2 2026, worth a combined $640K — down 48% from $1.23M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new YDES positions and 0 closed out — a net gain of 5 holders — while 4 added to existing stakes and 1 trimmed.
The largest buyer was Garrett Wealth Advisory Group, opening a new position worth an estimated $378K. The largest seller was Morgan Stanley, cutting an estimated $282.
- 13 institutional investors held YD Bio Ltd (YDES) as of Q2 2026, up from 8 in Q1 2026.
- Funds reported $640K of YD Bio Ltd stock for Q2 2026, down 48% quarter-over-quarter.
- 5 funds opened new YD Bio Ltd positions in Q2 2026 and 0 closed out, a net change of +5 holders.
- The largest YD Bio Ltd buyer in Q2 2026 was Garrett Wealth Advisory Group, an estimated $378K added.
- The largest YD Bio Ltd seller in Q2 2026 was Morgan Stanley, an estimated $282 sold.
Based on aggregated 13F filings for Q2 2026.